Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
By Leah Sherwood, Rashmi Kanagal-Shamanna, MD - Last Updated: February 13, 2023Rashmi Kanagal-Shamanna, MD, of the MD Anderson Cancer Center, discusses the optical genome mapping platform and the clinical implications the technology will have for patients with acute myeloid leukemia and myelodysplastic syndromes.
Advertisement
Related Posts
Early deaths remain a barrier against understanding a cure-for-all.
Researchers found that sabatolimab at 400 mg and 800 mg were well tolerated, as cytopenias occurred at low rates.
All response-evaluable patients attained a morphologic remission, translating into a 100% overall response rate.
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
This editorial outlines treatments for relapsed AML, T-Cell activation, and more.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.